Earnings results for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. is expected* to report earnings on 04/29/2021 before market open. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 9 analysts’ forecasts, the consensus EPS forecast for the quarter is $-1.75. The reported EPS for the same quarter last year was $-1.62.
Alnylam Pharmaceuticals last issued its earnings results on February 10th, 2021. The biopharmaceutical company reported ($2.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.76) by $0.33. The business earned $163.56 million during the quarter, compared to analysts’ expectations of $142.49 million. Alnylam Pharmaceuticals has generated ($8.11) earnings per share over the last year. Alnylam Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Thursday, April 29th, 2021.
Analyst Opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY)
17 Wall Street analysts have issued ratings and price targets for Alnylam Pharmaceuticals in the last 12 months. Their average twelve-month price target is $166.81, predicting that the stock has a possible upside of 16.22%. The high price target for ALNY is $235.00 and the low price target for ALNY is $91.00. There are currently 9 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of “Hold.”
Alnylam Pharmaceuticals has received a consensus rating of Hold. The company’s average rating score is 2.47, and is based on 8 buy ratings, 9 hold ratings, and no sell ratings. According to analysts’ consensus price target of $166.81, Alnylam Pharmaceuticals has a forecasted upside of 16.2% from its current price of $143.53. Alnylam Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Dividend Strength: Alnylam Pharmaceuticals (NASDAQ:ALNY)
Alnylam Pharmaceuticals does not currently pay a dividend. Alnylam Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Alnylam Pharmaceuticals (NASDAQ:ALNY)
In the past three months, Alnylam Pharmaceuticals insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $884,352.00 in company stock. Only 3.50% of the stock of Alnylam Pharmaceuticals is held by insiders. 92.35% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Alnylam Pharmaceuticals (NASDAQ:ALNY
Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($7.32) to ($6.21) per share. The P/E ratio of Alnylam Pharmaceuticals is -18.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Alnylam Pharmaceuticals is -18.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Alnylam Pharmaceuticals has a P/B Ratio of 11.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here